Biomea Fusion Reveals Lasting Success for Short-Term Type 1 Diabetes Treatment

Redwood City, Monday, 27 April 2026.
Biomea Fusion’s icovamenib boosted natural insulin markers by 52%. Remarkably, this unprecedented benefit in Type 1 diabetes patients persisted for a full year following just a 12-week treatment.